Year: 2026
Type: article
Abstract: INTRODUCTION: Neuritin-1 (NRN1) was identified as a synaptic protein associated with cognitive resilience to Alzheimer's disease (AD). METHODS: Target risk score and cell type expression profiles were generated for NRN1 using methods developed by the Emory-Sage-SGC-JAX Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) Center and Seattle Alzheimer's Disease Brain Cell Atlas (SEA-AD). Antibody characterization was conducted using Western blots and densitometry to assess the relative protein abundances of NRN1 in rodents, humans, and cell models. RESULTS: NRN1 has a TREAT-AD target risk score of 3.29 out of 5. Based on single-nucleus RNA sequencing from SEA-AD, NRN1 expression in excitatory neurons tends to decrease with increasing donor pseudo-progression. Abcam ab64186 polyclonal NRN1 antibody detects NRN1 protein in vitro and in vivo at molecular weights that suggest NRN1 forms a homodimer. NRN1 protein abundance is comparable among controls and primary tauopathy cases, as well as Tau P301S mice and non-transgenic littermates at 3 and 9 months. DISCUSSION: These findings advance the investigation of NRN1 as a therapeutic candidate for AD.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.71149
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
Awards: UAB Alzheimer's Disease Research Center, Synaptic Resilience to Tau in Alzheimer's Disease, G518313953, G606612931, Defining the Neuroprotective Mechanisms of Neuritin-1 in Cognitive Resilience to Alzheimer's Disease, G9000078916, G9000111905, G9000173445, G9000286694, Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease, Goizueta Alzheimer's Disease Research Center
OpenAlex ID: W7127996659